Cargando…

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment

BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary cause of end-stage kidney disease. Currently, tolvaptan is the only treatment that has proven to delay disease progression. The most notable side effect of this therapy is drug-induced liver injury; howeve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez-Espinosa, Diana, Broseta, José Jesús, Bastida, Carla, Álvarez-Mora, María Isabel, Nicolau, Carlos, Alvarez, Cristina, Agraz-Pamplona, Irene, Sánchez-Baya, Maya, Furlano, Mónica, Ruiz, César, Quintana, Luis F., Piñeiro, Gastón J., Poch, Esteban, Torra-Balcells, Roser, Blasco, Miquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2023
Materias:	Clinical Practice: Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137304/ https://www.ncbi.nlm.nih.gov/pubmed/36088902 http://dx.doi.org/10.1159/000526368

Ejemplares similares

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Autosomal dominant polycystic kidney disease: possibly the least silent cause of chronic kidney disease
por: Torra, Roser, et al.
Publicado: (2021)

Autosomal dominant polycystic kidney disease in young adults
por: Martínez, Víctor, et al.
Publicado: (2022)

Recent advances in the clinical management of autosomal dominant polycystic kidney disease
por: Torra, Roser
Publicado: (2019)

Comparative analysis of tools to predict rapid progression in autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2021)

Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Dietary Aspects and Drug-Related Side Effects in Autosomal Dominant Polycystic Kidney Disease Progression
por: Quiroga, Borja, et al.
Publicado: (2022)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

The management of polycystic liver disease by tolvaptan
por: Takenaka, Tsuneo, et al.
Publicado: (2020)

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
por: Gansevoort, Ron T., et al.
Publicado: (2016)

Safety and Tolerability of Tolvaptan in an Autosomal Dominant Polycystic Kidney Disease Spanish Cohort: A Real-World Experience
por: Guerra-Torres, Xavier E, et al.
Publicado: (2020)

Effect of tolvaptan on renal involvement in patients with autosomal dominant polycystic kidney disease according to different gene mutations
por: Moriyama, Tomofumi, et al.
Publicado: (2020)

Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Naranjo, Javier, et al.
Publicado: (2022)

Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
por: Mekahli, Djalila, et al.
Publicado: (2023)

Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis
por: Lioudis, Michael, et al.
Publicado: (2023)

Feasibility of artificial intelligence-based decision supporting system in tolvaptan prescription for autosomal dominant polycystic kidney disease
por: Shin, Jung Hyun, et al.
Publicado: (2023)

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
por: Müller, Roman-Ulrich, et al.
Publicado: (2021)

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017)

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
por: Muto, Satoru, et al.
Publicado: (2017)

The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial
por: Uchiyama, Kiyotaka, et al.
Publicado: (2021)

Tolvaptan ameliorated kidney function for one elderly autosomal dominant polycystic kidney disease patient: A case report
por: Zhou, Li, et al.
Publicado: (2022)

Efficacy and safety of tolvaptan versus placebo in the treatment of patients with autosomal dominant polycystic kidney disease: a meta-analysis
por: Lu, Jingkui, et al.
Publicado: (2022)

How genomics reclassifies diseases: the case of Alport syndrome
por: Torra, Roser, et al.
Publicado: (2020)

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing
por: Trujillano, Daniel, et al.
Publicado: (2014)

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2hva2ndg4dfvlks686lcbpe65p